Immuneering Corporation (IMRX)
1.96
0.01 (0.51%)
At close: Jan 15, 2025, 2:38 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Net Income | -53.47M | -50.51M | -33.54M | -17.04M | -7.71M |
| Depreciation & Amortization | 352.08K | 796.79K | 159.07K | 79.31K | 18.08K |
| Stock-Based Compensation | 5.73M | 4.06M | 1.80M | 1.09M | 596.63K |
| Other Working Capital | 119.84K | -276.56K | 751.10K | 357.58K | -465.00K |
| Other Non-Cash Items | -601.59K | -166.21K | 130.24K | 349.96K | 1.48M |
| Deferred Income Tax | n/a | n/a | -307.49K | -349.96K | 739.03K |
| Change in Working Capital | -974.64K | 1.72M | 900.42K | 1.25M | 437.13K |
| Operating Cash Flow | -48.97M | -44.10M | -30.85M | -14.62M | -4.44M |
| Capital Expenditures | -342.75K | -742.48K | -60.79K | -53.41K | -20.53K |
| Acquisitions | n/a | -41.83M | 70.35K | n/a | n/a |
| Purchase of Investments | -44.66M | -50.10M | -75.63M | n/a | n/a |
| Sales Maturities Of Investments | 52.30M | 92.68M | 75.62M | n/a | n/a |
| Other Investing Acitivies | n/a | 41.83M | -75.62M | n/a | n/a |
| Investing Cash Flow | 7.30M | 41.83M | -75.62M | -53.41K | -20.53K |
| Debt Repayment | n/a | n/a | n/a | n/a | 3.83M |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 241.07K | 19.00K | 23.95M | 37.98M | 9.52M |
| Financial Cash Flow | 28.44M | 19.00K | 144.26M | 37.98M | 17.17M |
| Net Cash Flow | -13.23M | -2.25M | 37.80M | 23.31M | 12.71M |
| Free Cash Flow | -49.31M | -44.84M | -30.91M | -14.67M | -4.46M |